The BLOC1S2 Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the human BLOC1S2 gene has been disrupted. This model provides a loss-of-function system for the BLOC-1 complex subunit BLOC1S2, allowing researchers to investigate its role in endosomal cargo sorting and lysosome-related organelle (LRO) biogenesis without clonal selection artifacts. The polyclonal format preserves biological variability, reflecting heterogeneous T lymphocyte responses.
The knockout was engineered in Jurkat cells, an immortalized human T lymphocyte line originally derived from a patient with acute T cell leukemia. Jurkat cells are a cornerstone model in immunology, extensively used to dissect T cell receptor signaling, apoptosis, and HIV pathogenesis. Their robust culture characteristics and well-defined intracellular pathways make them particularly suited for studying genes involved in secretory lysosome function and immune cell effector mechanisms.
BLOC1S2 is a core subunit of the octameric BLOC-1 complex, which is essential for LRO biogenesis, including melanosomes, platelet dense granules, and cytotoxic T lymphocyte lytic granules. The complex physically interacts with the AP-3 adaptor and SNARE fusion machinery, and contains subunits such as DTNBP1, SNAPIN, and PLDN. BLOC1S2 expression is activated by the transcription factors MITF and TFEB downstream of cAMP signaling, and its gene product mediates sorting of cargoes??including TYRP1 and PMEL to melanosomes and perforin and granzyme B to lytic granules??via endosomal trafficking. Disruption of BLOC1S2 therefore impairs BLOC-1 function, causing mis-sorting of these proteins and defective LRO maturation, a hallmark of Hermansky-Pudlak syndrome.
In the Jurkat cellular context, BLOC1S2 knockout directly compromises the biogenesis of secretory lysosomes, the LROs that store and release cytotoxic proteins. Loss of BLOC1S2 disrupts the targeted delivery of perforin and granzyme B, potentially diminishing T cell cytotoxic capacity. This model thus offers a physiologically relevant platform to examine how BLOC-1 complex defects impact immune effector functions, providing insights into the immunodeficiency aspects of Hermansky-Pudlak syndrome and related pigmentation and bleeding disorders.
Applications of these polyclonal knockout cells include co-immunoprecipitation to assess BLOC-1 complex integrity, electron microscopy for LRO ultrastructure analysis, and RT-qPCR or Western blotting for granzyme B and perforin quantification. Immunofluorescence for LAMP1 reveals lysosomal distribution changes, while flow cytometry profiles granule content. Lytic exocytosis assays directly measure secretory function, and the model is amenable to high-throughput screens for trafficking modulators. For additional information or custom inquiries, contact Ascent Research.
